# A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age

> **NCT05900154** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 128 (actual)

## Conditions studied

- RESPIRATORY SYNCYTIAL VIRUS (RSV)

## Interventions

- **BIOLOGICAL:** RSVpreF 120 µg
- **BIOLOGICAL:** RSVpreF 60 µg

## Key facts

- **NCT ID:** NCT05900154
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-22
- **Primary completion:** 2024-02-29
- **Final completion:** 2024-02-29
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05900154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05900154, "A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05900154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*